% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Weberpals:142590,
author = {J. Weberpals$^*$ and L. Jansen$^*$ and O. J. Müller and H.
Brenner$^*$},
title = {{L}ong-term heart-specific mortality among 347 476 breast
cancer patients treated with radiotherapy or chemotherapy: a
registry-based cohort study.},
journal = {European heart journal},
volume = {39},
number = {43},
issn = {1522-9645},
address = {Oxford},
publisher = {Oxford University Press},
reportid = {DKFZ-2019-00308},
pages = {3896 - 3903},
year = {2018},
abstract = {Breast cancer survival has improved throughout the last
decades, but treatment-induced cardiotoxicity remains a
major concern. This study aimed to investigate competing
causes of death and prognostic factors within a large cohort
of breast cancer patients and to describe the heart-specific
mortality in relation to the general population.In this
registry-based cohort study, women diagnosed with breast
cancer between 2000 and 2011, who were treated with
radiotherapy or chemotherapy and followed until 2014, were
identified from the Surveillance, Epidemiology, and End
Results-18 (SEER-18) database. Cumulative mortality
functions were computed. To investigate heart-specific
mortality relative to the general population, long-term
(≥10 years) standardized mortality ratios (SMRs) were
calculated. Prognostic factors for heart-specific mortality
were assessed by calculating cause-specific hazard ratios
(HRcs) with corresponding $95\%$ confidence intervals using
the Cox proportional hazards regression. Subgroup analysis
on intermediate-term mortality according to molecular
subtypes, for which information was available since 2010,
was performed. In total, 347 476 breast cancer patients
were eligible to be included in the study. Among all
possible competing causes of death, breast cancer accounted
for the highest cumulative mortality. Compared with the
general population, heart-specific mortality of breast
cancer patients treated with radiotherapy or chemotherapy
was lower [SMRoverall 0.84 (0.79-0.90)]. In subgroup
analysis, human epidermal growth factor receptor 2
(HER2)-positive subtype was not associated with increased
heart-specific mortality relative to HER2-negative patients
[HRcs 0.96 (0.70-1.32)].Heart-specific mortality among
breast cancer survivors is not increased compared with the
general population. Human epidermal growth factor receptor
2-positive patients do not have increased heart-specific
mortality compared to HER2-negative patients.},
cin = {C070 / G110 / L101},
ddc = {610},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)G110-20160331 /
I:(DE-He78)L101-20160331},
pnm = {323 - Metabolic Dysfunction as Risk Factor (POF3-323)},
pid = {G:(DE-HGF)POF3-323},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29635274},
doi = {10.1093/eurheartj/ehy167},
url = {https://inrepo02.dkfz.de/record/142590},
}